

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

GSK3 POLYPEPTIDES

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application
5 No. 60/221,242 filed July 27, 2000, where this provisional application is incorporated
herein by reference in its entirety.

BACKGROUND OF THE INVENTION

Field of the Invention

The invention provides materials and methods relating to identification and
10 optimization of selective inhibitors of glycogen synthase kinase 3 (GSK3), and also relates
to methods of treating a condition mediated by GSK3 activity. Such conditions include
Alzheimer's disease, type 2 diabetes, and inflammation.

Description of the Related Art

Glycogen synthase kinase 3 (GSK3) is a proline-directed serine/threonine
15 kinase originally identified as an activity that phosphorylates glycogen synthase as
described in Woodgett, *Trends Biochem Sci.* 16:177-181 (1991). The role in glucose
metabolism has been elaborated recently in Summers et al., *J. Biol. Chem.* 274:17934-
17940 (1999). GSK3 consists of two isoforms, α and β , and is constitutively active in
resting cells, inhibiting glycogen synthase by direct phosphorylation. Upon insulin
20 activation, GSK3 is inactivated, thereby allowing the activation of glycogen synthase and
possibly other insulin-dependent events. GSK3 is inactivated by other growth factors or
hormones that, like insulin, signal through receptor tyrosine kinases. Examples of such
signaling molecules include IGF-1 and EGF as described in Saito et al., *Biochem. J.*
303:27-31 (1994), Welsh et al., *Biochem. J.* 294:625-629 (1993), and Cross et al., *Biochem.*
25 *J.* 303:21-26 (1994). GSK3 has been shown to phosphorylate β -catenin as described in
Peifer et al., *Develop. Biol.* 166:543-56 (1994). Other activities of GSK3 in a biological

context include GSK3's ability to phosphorylate tau protein *in vitro* as described in Mandelkow and Mandelkow, *Trends in Biochem. Sci.* 18:480-83 (1993), Mulot et al., *Febs Lett* 349: 359-64 (1994), and Lovestone et al., *Curr. Biol.* 4:1077-86 (1995), and in tissue culture cells as described in Latimer et al., *Febs Lett* 365:42-6 (1995). Selective inhibition
 5 of GSK3/may be useful to treat or inhibit disorders mediated by GSK3 activity.

There is a need in the art for compositions and molecules that bind to or interact with GSK3, thereby mediating GSK3 activity. The invention meets this need by providing crystallizable GSK3 polypeptides useful for design and optimization of GSK3 inhibitors.

10 BRIEF SUMMARY OF THE INVENTION

The invention provides GSK3 β molecules with N- and C-terminal truncations, wherein the molecules are capable of crystallization.

The invention further provides GSK3 β molecules truncated at amino acid R³⁴⁴, R³⁵⁴, T³⁶⁴, A³⁷⁴, and I³⁸⁴.

15 The invention provides a polypeptide consisting essentially of SEQ ID NO:2 or SEQ ID NO:3, polynucleotides encoding these polypeptides, and vectors comprising these polynucleotides.

The invention still further provides GSK3 β molecules wherein translation of the molecule begins at G³⁴, T³⁹, P⁴⁴, D⁴⁹ or V⁵⁴.

20 The invention also provides GSK3 α molecules with N- and C-terminal truncations, wherein the molecules are capable of crystallization.

The invention further provides a GSK3 α molecule wherein translation of the molecule begins at S⁹⁷ and ends at S⁴⁴⁷, polynucleotides encoding this polypeptide, and vectors comprising these polynucleotides.

25 The invention further provides a method of identifying a GSK3 polypeptide capable of crystallization, comprising: (a) providing a truncated GSK3 polypeptide; (b) testing the polypeptide for formation of crystals.

The invention also provides GSK3 polypeptides capable of interacting with inhibitors of GSK3.

The invention further provides a method of identifying an enzymatically active GSK3 polypeptide, comprising: (a) providing a truncated GSK3 polypeptide; (b) contacting the polypeptide with a substrate of GSK3; and (c) measuring the kinase activity of the polypeptide after contacting the polypeptide with the substrate, wherein the polypeptide is active if it shows $>0.01 \times$ the activity of the full-length enzyme and preferably $>0.1 \times$ the activity of the full-length enzyme.

BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE IDENTIFIERS

10 Figure 1 provides the polypeptide sequence of human GSK3 β (SEQ ID NO:1).

Figure 2 provides the polypeptide sequence of truncated GSK3 β polypeptide 557 (SEQ ID NO:2). The first ten amino acids represent a Glu-tag, followed by a Gly linker before Met at position 1.

15 Figure 3 provides the polypeptide sequence of truncated GSK3 β polypeptide 580 (SEQ ID NO:3). The first ten amino acids represent a Glu-tag, followed by a Gly linker before Gly at position 34.

Figure 4 provides the polypeptide sequence of human GSK3 α (SEQ ID NO:4).

20 Figure 5 provides the polypeptide sequence of human GSK3 α truncated at position 447 (SEQ ID NO:5).

Figure 6 provides the polypeptide sequence of human GSK3 α truncated at position 97 (SEQ ID NO:6).

25 Figure 7 provides the polypeptide sequence of human GSK3 α from position 97 to position 447 (SEQ ID NO:7).

DETAILED DESCRIPTION OF THE INVENTION

The invention provides materials and methods for identifying and optimizing inhibitors of GSK3, including GSK3 α and GSK3 β . The provided materials include C- and N-terminal truncated GSK3 β molecules that are capable of crystallization and may, but need not, retain GSK3 kinase activity, preferably more than 0.01 x the activity of the full-length enzyme and more preferably more than 0.1 x the activity of the full-length enzyme. There is a need in the art for such inhibitors, in view of the role of GSK3 in a variety of diseases and conditions, including Alzheimer's disease, type 2 diabetes and inflammation. Such inhibitors can be identified, and identified inhibitors can be optimized, using the crystallizable GSK3 polypeptides of the invention.

The invention provides a variety of GSK3 β polypeptides that differ from the native polypeptide at the C- and/or N-terminus. The amino acid sequence of GSK3 β is shown in Figure 1 (SEQ ID NO:1). Included within the scope of the invention are any and all truncations of GSK3 β polypeptide wherein the truncated polypeptide is capable of crystallization and may, but need not, retain kinase activity as measured using the kinase assays described herein. Persons of skill in the art will realize that limited mutation of the protein, or certain post-translational modifications, might be sufficient to inactivate the kinase yet retain the essential 3D structure. Such inactive but structurally related molecules would also be useful for the design and optimization of inhibitors. Kinase assays are disclosed in U.S. Patent Nos. 6,057,117 and 6,057,286, which are incorporated herein by reference. The percent activity that is retained, if any, is not crucial. Methods of assaying activity in the presence and absence of an inhibitor are described herein.

The invention provides numerous truncated GSK3 β polypeptides that meet these criteria. A preferred polypeptide is designated BV557 in which the C-terminal amino acid is R³⁸⁴. This molecule has been successfully crystallized. Additional active polypeptides include those with truncations at amino acid R³⁴⁴, R³⁵⁴, A³⁷⁴, and I³⁸⁴.

The invention also provides truncated GSK3 α polypeptides, including a GSK3 α polypeptide beginning at S⁹⁷ and ending at S⁴⁴⁷.

Additional truncated GSK3 polypeptide include those beginning with an N-terminal amino acid that differs from that of the native protein in that 1 or more amino acids are deleted from the N-terminus. Preferred N-terminal truncations include GSK3 β molecules wherein translation of the molecule begins at G³⁴, T³⁹, P⁴⁴, D⁴⁹ or V⁵⁴. An
 5 example is BV580 (amino acids 34 to 384) which has been crystallized.

The invention is not limited to these disclosed truncated molecules. Using the methods and assays described herein, one of skill can construct additional truncated molecules, such as those having 36-76 amino acids deleted from the C-terminus, and/or 35-54 amino acids deleted from the N-terminus. Such deletions can occur individually, or a
 10 polypeptide can have both an N-terminal deletion and a C-terminal deletion. It is preferable but not necessary that the kinase domain remain relatively intact as reflected by the detection of enzymatic activity, such as by using the assays described herein. It is also desirable, although not essential, that the enzymatic activity be capable of inhibition by a known GSK3 inhibitor, such as lithium. A truncated molecule meeting these criteria will
 15 be suitable for testing GSK3 inhibitors as potential therapeutic agents, and for optimizing GSK3 inhibitors.

A truncated GSK3 β polypeptide of the invention can consist of between about 250 and 419 contiguous amino acids of SEQ ID NO:1; preferably between about 278 and 419 contiguous amino acids of SEQ ID NO: 1; more preferably between about 285 and
 20 384 contiguous amino acids of SEQ ID NO:1; and most preferably between about 351 and 384 contiguous amino acids of SEQ ID NO:1. Preferred truncated GSK3 β polypeptides include those beginning at amino acid 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, or 62 of SEQ ID
 25 NO:1, and ending at amino acid 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418 or 419 of SEQ ID

NO:1. The polypeptide can begin with any one of the listed beginning amino acids and end with any one of the ending amino acids. Exemplary and non-limiting embodiments begin at amino acid 34, 39, 44 or 54 and end at amino acid 420. Other particularly preferred
5 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, or 420.

The truncated GSK3 α polypeptide of the invention can consist of between about 182 and 482 contiguous amino acids of SEQ ID NO: 4, preferably between about
10 182 and 386 contiguous amino acids of SEQ ID NO:4, more preferably between about 182 and 351 contiguous amino acids of SEQ ID NO:4, and most preferably from about S⁹⁷ to S⁴⁴⁷ of SEQ ID NO:4.

The truncated GSK3 polypeptides can be prepared by any method known in the art. One method involves expression of a suitably prepared polynucleotide encoding a
15 polypeptide having the desired truncation. For example, a preferred polypeptide of the invention, BV557, was prepared by creating a construct encoding GSK3 β starting at M¹ and ending at I³⁸⁴, as described in the Examples. Briefly, insect cells were transfected with baculovirus vector (designated pBlueBac4.5.Glu.GSK3B.DC.I384#28), which encodes BU557, and the protein was extracted from the lysed cells. The protein was purified by
20 affinity chromatography using an anti glu-tag monoclonal antibody immobilized on a Sepharose column. Activity of the purified protein was assayed using the *in vitro* kinase assay described in U.S. Patent No. 6,057,286.

The Examples herein describe the production of BV557, BV580, and other truncated GSK3 polypeptides by expression of vectors encoding the polypeptides, followed
25 by isolation and purification of the polypeptides. The polypeptide can also be produced by enzymatic cleavage of a native GSK3 protein, using methods known in the art. Other suitable methods include expression of a polynucleotide encoding a truncated polypeptide in a variety of cell types, including mammalian, bacterial, or yeast cells. However, the

preferred cell for expression of the polypeptide is an insect cell, preferably a baculovirus-infectable insect cell, such as a Sf9 cell.

The invention also provides unphosphorylated forms of GSK3 wherein the ATP binding site is identical to that of the wild-type protein. Such forms include Y216 non-phosphorylated GSK3 β and Y279 non-phosphorylated GSK3 α . Other forms include
5 constructs with at least one amino acid change that prevents phosphorylation, such as GSK3 β in which Y216 is changed to F216, and GSK3 α in which Y279 is changed to F279. These forms are suitable for inhibitor binding assays to identify inhibitors of GSK3. The invention provides a GSK3 β molecule in which position 216 is not phosphorylated. We
10 have demonstrated that a GSK3 β peptide with Y216 mutated to F216 crystallized and exhibits a structure in which the ATP-binding site is not substantially different from the un-mutated peptide.

Additional single and multiple amino acid changes include S⁹ to A⁹ in GSK3 β and S²¹ to A²¹ in GSK3 α .

15 These changes in phosphorylation, or ability to be phosphorylated, are optionally incorporated into the truncated forms of GSK3 α and GSK3 β disclosed herein.

The invention therefore provides GSK3 molecules suitable for design and optimization of inhibitors of GSK3 as pharmaceutical agents.

The GSK3 constructs of the invention are capable of crystallization. In
20 purified form the constructs bind to inhibitors in a manner that is comparable to inhibitor binding to the native GSK3 polypeptide, due to the retention of the correct folding conformation at the inhibitor binding site. Potential to crystallize is measured using a variety of assays including specific activity, aggregation, microheterogeneity. (See, for example, Table 1). These parameters are indicative of the purity of the preparation and of
25 the solubility of the construct. The specific activity is also a preferred assay for detecting binding of an inhibitor to the correct binding site of the GSK3 construct. Another suitable method is fluorescence polarization. Briefly, a putative inhibitor, with an attached fluorophore, tumbles freely in solution. Thus when the fluorophore is excited by polarized light, the emitted light which is produced after a finite delay now has random polarity and

the emitted light is no longer polarized. In the presence of a GSK3 construct with an intact inhibitor binding site, the tumbling rate is slowed sufficiently to ensure that, even though the light emission is delayed with respect to the excitation, the fluorophore has only moved very slightly. Thus, the excited light maintains polarization. A measurement of
5 fluorescence polarization therefore indicates whether or not the GSK3 construct is suitable for identifying and optimizing an inhibitor. The fluorophore can be attached to a compound such as staurosporine (ICN Pharmaceuticals, Inc., Costa Mesa, CA). GSK3 constructs may not retain kinase activity, but their inhibitor binding can still be assessed using fluorescence polarization assays.

10 The term "truncated glycogen synthase kinase 3" or "truncated GSK3" as used herein refers to GSK3 α or GSK3 β . GSK3 is a protein originally identified by its phosphorylation of glycogen synthase as described in Woodgett et al, *Trends Biochem Sci*, 16:177-181 (1991). Synonyms of GSK3 are tau protein kinase I (TPK I), FA kinase and kinase FA. Mammalian forms of GSK3 have been cloned as described in Woodgett,
15 *EMBO J.* 9(8):2431-2438 (1990). Inhibitors of truncated GSK3 polypeptides can be inhibitors of any of the known forms of GSK3, including either GSK3 α or GSK3 β or both. Truncated polypeptides of the invention possess one or more of the bioactivities of the GSK3 protein, including kinase activities such as polymerizing tau protein, or phosphorylating glycogen synthase, for example. Thus, truncated GSK3 polypeptides
20 useful for designing and optimizing inhibitors of GSK3 can have sequence identity of at least 40%, preferably 50%, preferably 60%, preferably 70%, more preferably 80%, and most preferably 90% to the amino acid sequence of the native protein, wherever derived, from human or nonhuman sources. The polynucleotides encoding a GSK3 polypeptide can have 60%, preferably 70%, more preferably 80%, more preferably 90% and most
25 preferably 95% sequence identity to a native polynucleotide sequence of GSK3. Also included, therefore, are alleles and variants of the native polynucleotide sequence such that the polynucleotide encodes an amino acid sequence with substitutions, deletions, or insertions, as compared to the native sequence.

The term "peptide substrate" refers to a peptide or a polypeptide or a synthetic peptide derivative that can be phosphorylated by GSK3 activity in the presence of an appropriate amount of ATP or a phosphate donor. Detection of the phosphorylated substrate is generally accomplished by the addition of a labeled phosphate that can be detected by some means common in the art of labeling, such as radiolabeled phosphate. The peptide substrate may be a peptide that resides in a molecule as a part of a larger polypeptide, or may be an isolated peptide designed for phosphorylation by GSK3.

As disclosed in U.S. Patent Nos. 6,057,117 and 6,057,286, *in vitro* methods of assaying GSK3 activity include constructing peptide substrates. The peptide substrate can be any peptide substrate phosphorylatable by GSK3, and may be a peptide substrate including the formula: anchor ligand-(X)_nSXXXS(X)_m (SEQ ID NO:8) (wherein X is any amino acid, n is any integer, m is any integer, and preferably $n + m + 5 < 20$, i.e. $n + m < 15$) prephosphorylated at the C terminal serine. The assay is performed by contacting the

substrate with truncated GSK3 polypeptide in the presence of γ -phosphate-ATP, a substrate anchor, and optionally a candidate inhibitor. The identifying an inhibitor of GSK3 kinase activity includes contacting a coupled to an anchor ligand with truncated GSK3 polypeptide in the labeled γ -phosphate-ATP, a substrate anchor, and candidate inhibitor,

measuring an incorporation of radiolabel into the peptide substrate, then, in a separate assay vessel contacting a peptide substrate coupled to an anchor ligand with truncated GSK3 in the presence of radiolabeled γ -phosphate-ATP, and a substrate anchor, and measuring incorporation of radiolabel into said peptide substrate; ultimately an inhibitor of truncated GSK3 kinase activity is identified by a reduction of label incorporation in the assay with the candidate inhibitor as compared to the assay without the candidate inhibitor.

To conduct the *in vitro* kinase assay of the invention using microwells, scintillant may be present by pre-coating the wells with a scintillant material, or by adding it later following a wash step, as described in Example 4. The scintillant can be obtained from Packard, Meridian, Conn. Wells coated with scintillant are then in addition coated with streptavidin, as a substrate anchor, where biotin is the anchor ligand on the peptide.

in 6057,117 only
SXXXS

Alternatively, the streptavidin can be present on agarose beads containing scintillant or may be coated on an otherwise untreated plate to which scintillant is added subsequently. In any event, the streptavidin in the wells binds the biotin that contacts it. Following an assay using radiolabeled ATP, the radiolabel incorporated into the phosphorylated substrate that has been conjugated to the biotin will cause the scintillant to emit light. Where the streptavidin is attached to agarose beads containing scintillant, binding a biotin-conjugated radiolabeled peptide substrate will cause the beads to scintillate. In both the case of the wells lined with the scintillant, and the agarose beads containing scintillant, a reduction in scintillation as compared to a control amount of scintillation measured under non-inhibitory conditions, indicates the presence of a functional inhibitor of GSK3 activity. If the peptide has been phosphorylated by GSK3 with ^{32}P -labeled or ^{33}P -labeled phosphate, radioactive decay will cause the scintillant present in a microwell or mixed in agarose beads that are present in the reaction mixture to emit light and the measure of the amount of light emitted will be a measure of the activity of GSK3 in the assay. Low activity of GSK3 observed in the presence of a candidate inhibitor, as compared to the activity of GSK3 in the absence of the inhibitor, may indicate that the inhibitor is functional and can inhibit GSK3 kinase activity. In any case, an excess of streptavidin over peptide should be loaded into each well or should be affixed to the agarose beads.

GSK3 inhibitory activity can be measured using a cell-free assay as disclosed in publication WO 99/65897, and as described in Example 4 herein. Activity can also be measured using a cell-based assay. Briefly, a cell line, such as a Cos cell line, is transfected with Tau and with a GSK3 polypeptide. The phosphorylation of Tau at a specific site is monitored using a monoclonal antibody, as phosphorylation at that site is dependent on GSK3 activity.

Exemplary polypeptides of the invention include the following truncated polypeptides with reference to SEQ ID NO:1:

GSK3 β truncated at R³⁴⁴

GSK3 β truncated at R³⁵⁴

GSK3 β truncated at T³⁶⁴

GSK3 β truncated at A³⁷⁴

GSK3 β truncated at I³⁸⁴

GSK3 β beginning at G³⁴

GSK3 β beginning at T³⁹

5 GSK3 β beginning at P⁴⁴

GSK3 β beginning at D⁴⁹

GSK3 β beginning at V⁵⁴

The above truncations can be combined, providing a GSK3 β polypeptide beginning at any of G³⁴, T³⁹, P⁴⁴, D⁴⁹, or V⁵⁴, and ending at any of R³⁴⁴, R³⁵⁴, T³⁶⁴, A³⁷⁴, or I³⁸⁴.

Other exemplary polypeptides of the invention include the following truncated polypeptides with reference to SEQ ID NO:4:

GSK3 α truncated at S⁴⁴⁷.

GSK3 α beginning at S⁹⁷.

15 GSK3 α beginning at S⁹⁷ and truncated at S⁴⁴⁷.

A truncated GSK3 polypeptide of the invention can be selected on the basis of one or more parameters. A polypeptide will preferably crystallize in a form that is similar to that of native GSK3, with correct folding at and around the inhibitor binding site.

20 Crystallization can be performed using a Crystal Screen Kit (Hampton Research, Laguna Niguel, CA), or methods described by Jancarik, J. et al., *J. Appl. Cryst.* 24:409-411, 1991. The potential of a polypeptide to form crystals can be evaluated on the basis of specific activity, purity, homogeneity, mass spectrometry, aggregation, and dynamic light scattering. A preferred truncated polypeptide will meet the following parameters: purity

25 of at least 90%; less than 100% aggregation at 4°C at two weeks; and less than 50% heterogeneity (50% or greater of the desired form). A most preferred truncated polypeptide will have a purity of at least 98%, no aggregation at 4°C at two weeks; and less than 5% heterogeneity (unphosphorylated form). Such parameters indicate that the polypeptide

preparation is likely to crystallize, making it suitable for discovering and optimizing GSK3 inhibitors.

A prerequisite for crystallization is to obtain a sufficiently concentrated stock of protein. Not all GSK3 constructs will remain soluble at the required
5 concentration. A preferred concentration is >1 mg/ml, more preferred is >5 mg/ml, and most preferred is >10 mg/ml.

The polypeptides disclosed herein as 557 (SEQ ID NO:2), 580 (SEQ ID NO:3), 458, and 524 meet the criteria described above (see Example 3). Polypeptide 458 consists of amino acids 1-420 of SEQ ID NO:1 plus the following addition at the N-
10 terminus: EFMPTEAMAAPKRVI (SEQ ID NO:8). Polypeptide 524 consists of amino acids 1-420 of SEQ ID NO:1 plus the following addition at the N-terminus: EYMPMEGGG (SEQ ID NO:9). Other modified or truncated GSK3 polypeptides can be prepared and tested as described herein.

EXAMPLES

The following examples are exemplary only, and are not intended to limit
5 the invention.

EXAMPLE 1

PREPARATION AND PURIFICATION OF GSK3 β CONSTRUCT 557

10 Lysis and Extraction. Insect cell slurry from Sf9 cells (about 10 g) from a 1 liter flask growth was combined with 30 ml of lysate buffer: 20mM Tris, pH 8.0 / 80mM NaCl / 1mM MgCl₂ / 1mM Arsenate / 1mM Tungstenate / 1mM PMSF / 0.5mg Leupeptin / 0.2 mg Aprotinin. Cells were lysed using a Dounce homogenizer. Improved extraction of the protein was accomplished by the addition of 5% glycerol and 0.2% octylglucoside. The
15 mixture was allowed to stir, on ice, for 30 minutes. The total lysate was centrifuged at 39000 x g for 25 minutes at 4°C. The resulting supernatant contained the extracted GSK3- β #557.

Ion Exchange Chromatography. The following materials and conditions were used: The resin was Fractogel EMD SO₃⁻ (M); the column diameter was 1.6cm and
20 the column volume was 10ml. The column was run at a flowrate of 90cm/hour using equilibration buffer of 20mM Na Phosphate / 5% Glycerol, pH 7.5. Chromatography was carried out at 4°C.

The lysate supernatant was diluted 1:1 with S-fractogel equilibration buffer, and loaded onto the equilibrated column. The column was washed with a total of 14
25 column volumes of equilibration buffer. The GSK3- β was eluted with a linear salt gradient, over 20 column volumes, to equilibration buffer plus 1M NaCl. 3ml/fraction was collected during gradient elution. The pool was made based on SDS-PAGE and Western blot results of the fractions collected. Fractions 13-24 were pooled.

Affinity Chromatography was performed using the following materials and procedures: The resin was anti glu-tag monoclonal antibody immobilized onto Protein G Sepharose, and the equilibration buffer was PBS / 0.3M NaCl / 0.2% octylglucoside / 10% Glycerol. The column diameter was 1.6cm and the column volume was 13ml. The flow rate was 30cm/hour during load and wash, and 15cm/hour during elution.

The S-Fractogel pool was loaded at 30cm/hour onto equilibrated column. The column was washed down to absorbance baseline with approximately 6 column volumes of equilibration buffer, and GSK3 β was eluted with 50 ml of equilibration buffer containing 2mg of elution peptide (EYMPTD). The flow rate during elution was lowered to 15cm/hour. 2ml/fractions were collected during the elution. Based on SDS-PAGE results, elution fractions 6-17 were pooled with a total volume of 24 ml.

Final Yield. The affinity column pool, at a concentration of 0.17mg/ml, contained 4.1 mg of GSK3 β #557. This translates to a final yield of 4.1mg purified 557 / liter of growth. Purity, after this 2 column purification, was estimated at >95% by visual inspection of SDS-PAGE results.

EXAMPLE 2

PREPARATION AND PURIFICATION OF GSK3 β CONSTRUCT 580

Extraction. SF9 cell paste from a 10 L fermentation was washed with 100 mL PBS (10 mM NaPi, pH7.5, 150 mM NaCl) and then resuspended with 300 mL of Buffer H (20 mM Tris, pH 7.5, 1 mM Tungstate, 1 mM Arsenate, 5 mM DTT, 10 μ g/mL Leupeptin, 1 μ g/mL pepstatin A, 10% glycerol, 0.35% Octyl glucoside, 1 mM Mg²⁺). Cells were homogenized in a 100-mL Dounce Homogenizer (20 strokes with pestle B). The combined homogenate was centrifuged in a Ti45 rotor at 40,000 rpm for 35 minutes to remove cell debris and nuclei. The supernatant from the centrifugation were carefully decanted and filtered through 0.45 μ filter.

S-Fractogel. 100 mL S-Fractogel (EM Science, Cat #18882) was packed into a 3.2 cm x 12.5 cm column and equilibrated with > 1 L of buffer A (20 mM Tris, pH

7.5, 10% glycerol). The filtrate from the previous step was loaded at 15 mL/min onto the column. The column was washed with 1 L of buffer A and then eluted with a linear gradient from 0 to 1 M NaCl in buffer A over 20 column volumes. The eluant was fractionated into 20 mL each. Fractions containing GSK3 were detected by Western Blot using anti-GSK antibody (Santa Cruz Biotech, Cat # SC-7291). The Western-Blot positive fractions were pooled and mixed with equal volume of buffer M (20 mM Tris, pH 7.5, 10% glycerol, 3.1 M NaCl) and filtered through a 0.45 μ filter. The filtrate was saved for Phenyl-650 M chromatography.

Phenyl-650 M. 37.5 mL Phenyl-650 M (Tosohass, Cat # 014943) was packed into a 2.2 x 10 cm column and equilibrated with 500 mL of buffer C (20 mM Tris, pH 7.5, 10% glycerol, 1.6 M NaCl). Filtrate from S-fractogel step was loaded onto the column at 7.5 mL/min. After the loading was completed, the column was washed with 6.5 cv buffer C and eluted with a linear gradient from 0% to 100% Buffer D (20 mM Tris, pH 7.5, 10% glycerol) over 20 column volumes. Fractions were collected at 15 mL each and GSK containing fractions were detected by Western Blot using anti-GSK antibody. The Western positive fractions were pooled and loaded onto a Glu-tag antibody affinity column.

Glu-tag antibody Affinity Chromatography. Use of a Glu-tag is described in Rubinfeld et al., *Cell* 65:1033-1042, 1991, and a hybridoma expressing anti-Glu-tag antibody is described in Grussenmyer et al., *PNAS* 82:7952-7954 (1985). 50 mg of the Glu-tag antibody was immobilized onto 25 mL of Affi-Gel 10 (BioRAD, Cat #153-6046) and packed into a 2.2 x 6.5 cm column. The column was equilibrated with 200 mL of buffer E (20 mM Tris, pH 7.5, 10% glycerol, 0.3 M NaCl, 0.2% Octylglucoside) and the fraction pool from the Phenyl-650 M step was loaded at 1.0 mL/min. After the loading was completed, the column was washed with 100 mL of buffer E and then eluted with 60 mL Glu-tag peptide (100 μ g/mL) in Buffer E and fractionated into 5 mL each. GSK containing fractions were detected with SDS-PAGE and Coomassie Blue staining. These fractions were pooled and concentrated to approximately 6 mg/mL in an Amicon concentrator using

a 10 k MWCO YM10 membrane. The concentrated material was then ready for crystallization.

EXAMPLE 3

5 ACTIVITY OF TRUNCATED GSK3 β POLYPEPTIDES

A reaction mixture was prepared containing 5.9 μ M prephosphorylated SGSG-linked CREB peptide (Wang et al., *Anal. Biochem.*, 220:397-402 (1994)) μ in reaction buffer (5mM Tris, pH 7.5, 5mM DTT; 1mM MgCl₂, 0.01% BSA) containing the
 10 desired amount of truncated GSK3 polypeptide. ATP was added (specific activity 5.3 Ci/mmol) to 25 μ M final concentration and the mixture was incubated for 20 min. at room temperature. The reaction was stopped by transferring 30 μ l onto a P81 filter disc (Whatman). The disc was washed four times in 150 ml of 75 mM H₃PO₄ for 5 minute each. The filter was air dried and counted under 5 ml scintillation fluid. The specific
 15 activity was counted by determining the ratio of counts (in cpm) by the mass of GSK3 in the reaction (in μ g).

The specific activity for construct 557 was 4.3×10^7 cpm/ μ g; for construct 458, 2.8×10^7 cpm/ μ g; and for construct 524, 2.2×10^7 cpm/ μ g.

Table 1

Construct	Purity	Mean Specific Activity	N	Concentration	Aggregation at 4 Degrees	Aggregation at RT	Heterogeneity
		cpm/ μ g		mg/ml			%
458	>98%	2.8×10^7	35	11.5	11% @ > 2 weeks	overnight	10-20% unphosphorylated
557	>98%	4.3×10^7	7	12.7	none @ > 2 weeks	overnight	5% unphosphorylated
524	>98%	2.2×10^7	24	10	ND		< 5% unphosphorylated

N = number of assays used to determine "mean specific activity."

5

EXAMPLE 4**SCREENING FOR GSK3 INHIBITORY ACTIVITY USING A CELL-FREE ASSAY**

Compounds to be tested as GSK3 inhibitors are dissolved in DMSO, then tested for inhibition of human GSK3 β . Expression of GSK3 β is described, for example, in Hughes et al., *Eur. J. Biochem.*, 203:305-11 (1992), which is incorporated herein by reference. An aliquot of 300 μ l of substrate buffer (30 mM tris-HCl, 10 mM MgCl₂, 2 mM DTT, 3 μ g/ml GSK3 β) and 0.5 μ M biotinylated prephosphorylated SGSG-linked CREB peptide (Chiron Technologies PTY Ltd., Clayton, Australia) is dispensed into wells of a 96 well polypropylene microtiter plate. 3.5 μ l /well of DMSO containing varying concentrations of each compound to be assayed or staurosporine (a known kinase inhibitor used as a positive control, or a negative control) (*i.e.*, DMSO only), is added and mixed thoroughly. The reactions is then initiated by adding 50 μ l/well of 1 μ M unlabeled ATP and $1-2 \times 10^7$ cpm γ^{33} P-labeled ATP, and the reaction is allowed to proceed for about three hours at room temperature.

While the reaction is proceeding, streptavidin-coated Labsystems "Combiplate 8" capture plates (Labsystems, Helsinki, Finland) are blocked by incubating them with 300 μ l/well of PBS containing 1% bovine serum albumin for at least one hour at room temperature. The blocking solution is then removed by aspiration, and the capture
5 plates are filled with 100 μ l/well of stopping reagent (50 μ M ATP/20 mM EDTA),

When the three hour enzyme reaction is finished, triplicate 100 μ l aliquots of each reaction mix are transferred to three wells containing stopping solution, one well on each of the three capture plates, and the well contents are mixed well. After one hour at room temperature, the wells of the capture plates are emptied by aspiration and washed five
10 times using PBS and a 12 channel Corning 430474 ELISA plate washer. Finally, 200 μ l of Microscint-20 scintillation fluid is added to each well of the plate. The plates are coated with plate sealers, then left on a shaker for 30 minutes. Each capture plate is counted in a Packard TopCount scintillation counter (Meridian, Connecticut) and the results are plotted as a function of compound concentration.

15 Compounds identified using this method can be further optimized by testing their ability to bind to truncated GSK3 polypeptides of the invention, using the fluorescence polarization assay, for example, for truncated polypeptides that do not exhibit GSK3 kinase activity. Alternatively, a truncated GSK3 polypeptide of the invention can be used in place of the native GSK3 protein.

20

EXAMPLE 5

SCREENING FOR INHIBITION OF TAU PROTEIN PHOSPHORYLATION

A. Transient Transfection of COS Cells with Expression Plasmid Encoding Truncated GSK3 and Tau Expression Plasmid Construction

25 COS cells are maintained in T25 tissue culture flasks in high glucose MEM medium / 5% fetal bovine serum. Cells from a confluent T25 flask are harvested and 80,000 cells/well are seeded into Corning 6-well tissue culture plates in a final volume of 2 ml/well of medium. The cells are left to grow at 37°C for 48 hours. The cells are then

washed twice in Opti-MEM containing no fetal bovine serum, and finally the cells are left in 1 ml of Opti-MEM.

Polynucleotide encoding tau protein is subcloned into plasmid pSG5 under an early SV40 promoter to generate a tau expression plasmid. The cloning of cDNA encoding tau protein is generally described in Goedert et al., *EMBO Journal*, 8(2):393-399 (1989), which is incorporated herein by reference. A GSK3 expression plasmid is prepared by subcloning polynucleotide encoding truncated GSK3 into pCG, which is an ApEVRF derivative described in Giese et al., *Genes & Development*, 9:995-1008 (1995) and Matthias et al., *Nucleic Acid Research*, 17:6418 (1989), both of which are incorporated herein by reference. The polynucleotide can encode any of the truncated GSK3 polypeptides of the invention.

The following solutions are prepared in 1.5 ml Eppendorf tubes:

Solution A: for each transfection, 2 µg of DNA (tau expression plasmid) and 0.7 µg of DNA (GSK3 expression plasmid) are diluted into 100 µl of Opti-MEM (Gibco BRL); Solution B: for each transfection, 8 µl of Lipofectamine reagent is diluted into 100 µl of Opti-MEM. The two solutions are combined, mixed gently, and incubated at room temperature for 45 minutes to allow DNA-liposome complexes to form. For each transfection, 0.8 ml of Opti-MEM is added to the tube containing the complexes. The diluted solution is mixed gently and overlaid onto the rinsed cells. The cells are incubated with the complexed DNA / Lipofectamine for 6 hours at 37°C in a CO₂ incubator. Following incubation, 1 ml of growth medium (high glucose MEM) with 20% FBS is added to each well and incubated at 37°C overnight. The medium is replaced with fresh, complete medium at 18 hours following the start of transfection, and the cells are left to grow at 37 °C for another 48 hours.

25 B. Tau Phosphorylation Inhibition assay

Two hours before harvesting, 2 µl of GSK3 inhibitor dissolved in DMSO is added to each well and incubated at 37°C. After 2 hours the medium is removed and the cells are rapidly frozen on the plates on dry ice and stored at -70°C. Cells are thawed on

ice in the presence of 200 μ l of lysing buffer (1% Triton[®] X-100, 20 mM Tris pH 7.5, 137 mM NaCl, 15% glycerol, 25 μ g/ml leupeptin, 1 μ g/ml pepstatin-A, 1 μ M PMSF, 21 μ g/ml aprotinin, 50 mM NaF, 50 mM β -glycerophosphate, 15 mM sodium pyrophosphate, 1 mM sodium orthovanadate). The contents of each well are centrifuged at 14,000 g, 4°C for 5 minutes and the supernatants transferred to clean tubes. At this point the lysates may be stored at -20°C.

C. ELISA to detect phosphorylated tau in cell lysates

Immulon 4 strips (Dynatech) are coated with monoclonal anti-phosphorylated tau (AT8, Polymedco, Inc.) at 5 μ g/ml in PBS containing Ca⁺⁺ and Mg⁺⁺, 10 100 μ l/well. After overnight incubation at 4°C, the strips are washed twice with washing buffer (PBS containing 0.05% Tween[®] 20) and blocked with PBS containing 1% BSA, 5% normal mouse serum and 0.05% Tween[®] 20 at room temperature for 1 hour. The strips are washed 5 times with washing buffer. Lysate (100 μ l) diluted 1:10 in PBS containing 1% BSA, 0.1% NaN₃ is added into each well and incubated at room temperature for 1 hour. 15 After washing, 100 μ l of 0.5 μ g/ml biotinylated monoclonal anti-(non-phosphorylated) tau (HT7, Polymedco, Inc.) in PBS-BSA is added into each well. Strips are washed 5 times and HRP-conjugated streptavidin is added, incubated at room temperature for 30 minutes and washed extensively with washing buffer. TMB substrate (Pierce) is used for color development and the reaction is stopped by adding an equal volume of 0.8 M sulfuric acid. 20 Strips are read on an ELISA plate reader using a 450 nm filter. The concentration of compound that inhibits tau phosphorylation to 50% of the maximal level (i.e., IC₅₀) is determined by fitting a sigmoidal curve to the plotted data.

Those skilled in the art will recognize, or be able to ascertain, using not 25 more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such specific embodiments and equivalents are intended to be encompassed by the following claims.

All patents, published patent applications, and publications cited herein are incorporated by reference as if set forth fully herein.